Marketing Spending Models - Innovation and Marketing in the Pharmaceutical Industry - page 577

Ching A, Ishihara M (2010) The effects of detailing on prescribing decisions under quality uncertainty.
Quant Mark Econ 8(2):123-165
Chintagunta PK, Desiraju R (2005) Strategic pricing and detailing behavior in international mar-
kets. Mark Sci 24(1):67-80
Chintagunta PK, Jiang R, Jin GZ (2009) Information, learning, and drug diffusion: the case of
Cox-2 inhibitors. Quant Mark Econ 7(4):399-443
Colsarici C, Vakratsas D (2010) Category-versus brand-level advertising messages in a highly
regulated environment. J Mark Res 47(6):1078-1089
Crawford GS, Shum M (2005) Uncertainty and learning in pharmaceutical demand. Econometrica
73(4):1137-1173
Dekimpe MG, Hanssens DM (1999) Sustained spending and persistent response: a new look at
long-term marketing profitability. J Mark Res 36(4):397-412
Dong X, Chintagunta PK, Manachanda P (2011) A new multivariate count data model to study
multi-category physician prescription behavior. Quant Mark Econ 9(3):301-337
Donhue JM, Berndt ER (2004) Effects of direct-to-consumer advertising on medication choice: the
case of antidepressants. J Publ Pol Market 23(2):115-127
Dorfman R, Steiner PO (1954) Optimal advertising and optimal quality. Am Econ Rev
44(December):826-836
EFPIA (2011) The pharmaceutical industry in figures, key data, 2011 update. European Federation
of Pharmaceuticals Associations, London. http://www.efpia.eu/uploads/roduecs/Documents/
igures_204inne-20110610-014en-vl.pdf . Accessed 27 July 2011
Fischer M, Albers S (2010) Patient- or physician-oriented marketing: what drives primary demand
for prescription drugs? J Mark Res 47(1):103-121
Fischer M, Shankar V, Clement M (2005) Can a late mover use international market entry strategy
to challenge the pioneer? MSI Report No. 05-118. Cambridge, MA: Marketing Science
Institute
Fischer M, Leeflang PSH, Verhoef PC (2010) Drivers of peak sales for pharmaceutical brands.
Quant Mark Econ 8(4):429-460
Fischer M, Shin H, Hanssens DM (2011) Brand performance volatility arising from marketing
spending behavior under competition. Working paper, University of California at Los Angeles
Fischer M, Albers S, Wagner N, Frie M (2011b) Dynamic marketing budget allocation across
countries, products, and marketing activities. Market Sci 30(4):568-585
Gönül FF, Carter F, Petrova E, Srinivasan K (2001) Promotion of prescription drugs and its impact
on physicians' choice behavior. J Mark 65(3):79-90
Gonzalez J, Sismeiro C, Dutta S, Stern P (2008) Can branded drugs benefit from generic entry? the
role of detailing and price in switching to non-bioequivalent molecules. Int J Res Mark 25:
247-260
Grabowski H, Vernon J (1990) A new look at the returns and risks to pharmaceutical R&D. Manag
Sci 36(7):804-821
Hahn M, Park S, Krishnamurthi L, Zoltners A (1994) Analysis of new product diffusion using a
four segment trial-repeat model. Mark Sci 13(3):224-247
Hanssens DM, Parsons LJ, Schultz RL (2001) Market response models, econometric and time
series analysis, 2nd edn. Kluwer Academic Publisher, Boston
IMS Health (2010) IMS integrated promotional services: total US promotional spend by type,
2009. http://www.imshealth.com/deployediles/imshealth/Global/Content/StaticFile/Top_
Line_Data/PromoUpdate2009.pdf . Accessed 12 July 2011
Hurwood DL (1968) How companies set advertising budgets. Conf Board Rec 5:34-41
Kotler P, Armstrong G (2010) Principles of marketing, 13th edn. Prentice Hall, Upper Saddle, NJ
Kremer STM, Bijmolt THA, Leeflang PSH, Wieringa JE (2008) Generalizations on the effective-
ness of pharmaceutical promotional expenditures. Int J Res Mark 25:234-246
Leeflang PSH, Wittink DR, Wedel M, Naert PA (2000) Building models for marketing decisions.
Kluwer Academic Publisher, Boston
Lilien GL (1979) ADVISOR 2: modeling the marketing mix decision for industrial products.
Manag Sci 25(2):191-204